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Abstract
Background: Ultra-deep pyrosequencing (UDPS) allows identification of rare HIV-1 variants and minority drug resistance
mutations, which are not detectable by standard sequencing.
Principal Findings: Here, UDPS was used to analyze the dynamics of HIV-1 genetic variation in reverse transcriptase (RT)
(amino acids 180–220) in six individuals consecutively sampled before, during and after failing 3TC and AZT containing
antiretroviral treatment. Optimized UDPS protocols and bioinformatic software were developed to generate, clean and
analyze the data. The data cleaning strategy reduced the error rate of UDPS to an average of 0.05%, which is lower than
previously reported. Consequently, the cut-off for detection of resistance mutations was very low. A median of 16,016
(range 2,406–35,401) sequence reads were obtained per sample, which allowed detection and quantification of minority
resistance mutations at amino acid position 181, 184, 188, 190, 210, 215 and 219 in RT. In four of five pre-treatment samples
low levels (0.07–0.09%) of the M184I mutation were observed. Other resistance mutations, except T215A and T215I were
below the detection limit. During treatment failure, M184V replaced M184I and dominated the population in combination
with T215Y, while wild-type variants were rarely detected. Resistant virus disappeared rapidly after treatment interruption
and was undetectable as early as after 3 months. In most patients, drug resistant variants were replaced by wild-type
variants identical to those present before treatment, suggesting rebound from latent reservoirs.
Conclusions: With this highly sensitive UDPS protocol preexisting drug resistance was infrequently observed; only M184I,
T215A and T215I were detected at very low levels. Similarly, drug resistant variants in plasma quickly decreased to
undetectable levels after treatment interruption. The study gives important insights into the dynamics of the HIV-1
quasispecies and is of relevance for future research and clinical use of the UDPS technology.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) displays very
high genetic variability, which is the primary obstacle for
development of an effective HIV vaccine and the reason for the
emergence of resistance during antiretroviral therapy (ART).
Within an HIV-1 infected individual, selective pressures, such as
the host immune response and ART, influence the evolution of the
virus. This leads to the formation of a diverse pool of closely
related virus variants called a quasispecies [1,2]. The genetic
diversity is caused by the error-prone reverse transcriptase (RT),
which generates an average of 3.4610
25 mutations per site and
generation [3,4], the high virion production rate and the short
generation time [5,6,7,8]. Finally, recombination events that occur
during reverse transcription also contribute to genetic variability
[9,10]. Consequently, point mutations, including those associated
with drug resistance, are spontaneously generated many times
every day even in patients who never have received ART [5].
Even though recent data indicate that minority drug resistance
variants may be associated with reduced treatment efficacy in
treatment-naı ¨ve individuals [11,12], little is still known about
variation in the relative abundance of preexisting resistance
mutations and if such variation has clinical significance.
Drug resistance does not generally develop in patients who are
adherent to modern combination antiretroviral treatment (cART),
but may develop very quickly during suboptimal treatment.
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cost, and therefore resistant virus variants are usually replaced by
wild-type variants if cART is interrupted. Studies have suggested
that these rebounding wild-type variants originate either from
wild-type virus that had been archived in latently infected cells
before start of therapy [13] or from continued evolution that leads
to reversion of resistance mutations [14,15].
Newly developed high-throughput sequencing technologies
have revolutionized genetic research. One such technology is
massive parallel pyrosequencing [16]. One application of this
technology is ultra-deep pyrosequencing (UDPS), which allows
identification of rare genetic variants and minority drug resistance
mutations, which are not detectable by standard genotypic
sequencing techniques [12,17,18,19].
The aim of this study was to use UDPS to investigate the in vivo
dynamics of HIV quasispecies in longitudinally collected plasma
samples from six individuals who started treatment before the
cART era. We analyzed a region of pol corresponding to amino
acids 180–220 in the RT. This region includes the following
important and well-defined drug resistance mutations to nucleo-
side RT inhibitors (NRTIs) and non-nucleoside RT inhibitors
(NNRTIs): L210W, T215Y/F and K219Q/E associated with
resistance to zidovudine (AZT) and stavudine (d4T); M184I/V
associated with resistance to lamivudine (3TC) and emtricitabine
(FTC); and Y181C/I/V, Y188C/L/H and G190S/A associated
with resistance to nevirapine (NVP), efavirenz (EFV) and etravirin
(ETR) [20]. We also studied so called T215 reversion mutations
(T215A/C/D/E/G/H/I/L/N/S/V) [21]. As the name indicates
these mutations are usually seen in patients who have failed and
later interrupted therapy with zidovudine (AZT) or stavudine
(d4T), which leads to ‘‘reversion’’ of the resistance mutations
T215Y and T215F, but nothing precludes that they may be
present as minority variants before therapy.
The sensitivity for detection of rare variants is primarily
determined by the number of virus templates that can be
successfully extracted and amplified from plasma samples and by
the error rate of PCR and UDPS [4]. Here, we have developed
optimized protocols to maximize HIV template input and new
bioinformatic software to clean the sequence data from PCR and
sequencing errors, which allowed us to detect genuine virus
variants that constituted as little as 0.05% of the HIV-1
quasispecies. This has to our knowledge not been achieved before
in studies of HIV-1 resistance. Interestingly, we found that even
with our highly sensitive UDPS methods, preexisting drug
resistance was infrequently observed. Thus, only M184I, T215A
and T215I were found at very low levels. During treatment failure,
wild-type variants were below the detections limit in all except one
patient. Finally, after treatment interruption drug resistant variants
in plasma decreased to undetectable levels as early as after three
month, which may be important for clinical management of
patients with previous treatment failure since our results suggests
that drug resistant variants is difficult in plasma even with this
sensitive technology. Moreover, our findings give important
insights into the dynamics of the HIV-1 quasispecies and are of
relevance for future research and clinical use of the UDPS
technology.
Materials and Methods
Ethical statement
Ethics application was approved by Regional Ethical Review
board in Stockholm, Sweden (Dnr 52/2008-77). Patients partic-
ipating in this study gave written informed consent according to
the Declaration of Helsinki.
Plasma samples
A total of 40 plasma samples from six HIV-1 subtype-B-infected
individuals were included in the study. Patients participating in this
study gave written informed consentaccordingto theDeclaration of
Helsinki. From each patient, longitudinally collected plasma
samples that had been stored at 270uCo r220uC, were selected
based on the patients’ treatment history and plasma viral load
(ranging from 17,900–1,600,000 HIV-1 RNA copies/mL). Infor-
mationabout the patients and the samples is summarized inTable 1
and Fig. 1. Allpatients had experienced virologicaltreatment failure
and all patients, except one, had later undergone treatment
interruption. The treatment histories of the patients differed, but
all started therapy before the cART era and all had received
regimens that contained 3TC, AZT and d4T. Five of six patients
were sampled before any treatment was initiated. All patients were
sampled two to four times during treatment, i.e. the first possible
sample after treatment initiation and additional samples obtained
during therapy failure. Finally, five patients were sampled during
treatment interruption.
RNA extraction, cDNA synthesis and PCR amplification
Considerable effort was invested in evaluating and comparing
different approaches for RNA extraction, cDNA synthesis and
PCR amplification, and substantial differences between methods
were observed (data not shown). The aim of the protocol was to
maximize the number of plasma HIV RNA molecules that were
extracted, reverse transcribed, PCR amplified and finally subject-
ed to UDPS. The final optimized protocol is presented below and
a detailed workflow is outlined in Fig. S1. HIV RNA was extracted
and purified with the RNeasy Lipid Tissue Mini Kit (Qiagen,
Hilden, Germany) using the QIAvac 24 vacuum minifold protocol
(Qiagen, Hilden, Germany) and the RNA was eluted in 40 mlo f
RNase free water. The amount of plasma used for extraction was
adjusted to the viral load (200 mL–1000 mL). The extracted viral
RNA (40 mL) was divided into five aliquots of 8 ml and reverse
transcribed with Thermoscript (Invitrogen, Carlsbad, California,
US) using the gene specific primer JA272 (see below) according to
the manufacturer’s instructions. The five 20 ml cDNA aliquots
from each sample were pooled into a total volume of 100 ml cDNA
before PCR with outer primers. The HIV-1 cDNA copy number,
i.e. actual number of viral templates subjected to UDPS, was
quantified for each sample using an in-house limiting dilution
PCR method adapted from Brinchmann et al. [22].
The cDNA was used to amplify 261 nucleotides spanning
amino acid positions 163 to 223 (position 3070 to 3209 in
HXB2, GenBank accession number K03455) of the reverse
transcriptase (RT) region of the pol gene with a nested PCR
approach using the Fast Start High Fidelity System (Roche,
Penzberg, Germany). The total 100 mlv o l u m eo fc D N Aw a s
divided into parallel outer PCR reactions each containing 5 ml
of cDNA. Next, the products from the outer PCR were pooled
and 2.5 ml was used in two inner PCR reactions. Both PCRs
were carried out as follows: one initial denaturation step of 95uC
for 2 min followed by 30 cycles of denaturation for 20 s at 94uC,
annealing for 20 s at 50uC ,a n de x t e n s i o nf o r9 0sa n daf i n a l6 -
min extension at 72uC. The primers used were, outer sense
primer JA269, outer antisense JA 272, inner sense JA329 and
inner antisense JA331 (for details on primers see Table S1). The
inner sense and antisense primers were linked to UDPS adapters
A and B, respectively. To distinguish each sample in the
m u l t i p l e x e dU D P S ,e i g h tu n i q u es e q u e n c et a g sw e r ei n s e r t e d
between the adaptor and the gene specific primer (for details on
the tag sequences see Table S2).
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Patient Sample Treatment
a Sampling
b RNA copies/ml
c Vol. (mL)
d Yield (%)
e No. of templ.
f Readsbefore
j Reads after
k
1 1 None 1995-02-23 274,000 500 2.4 3,300 18,541 15,000
2 3TC,AZT,PI 1997-04-09 41,300 1000 24 10,000 20,785 15,418
3 3TC,d4T,ddI 1998-04-02 55,500 1000 7.2 4,000 21,682 17,257
4 3TC,d4T,ddI 1998-09-09 58,700 1000 12 7,000 20,553 16,958
5 None 2000-02-28 210,000 1000 48 100,000 23,376 18,037
6 None 2000-09-21 966,000 500 100 570,000 21,811 18,141
2 1 None 1994-01-10 284,000 500 2.8 4,000 16,847 13,414
2 3TC,d4T,PI 1997-08-13 73,600 1000 9.5 7,000 22,113 19,291
3 3TC,d4T,PI 1998-01-27 17,900 1000 48 8,600 18,693 16,649
4 3TC,d4T,PI 1998-12-07 67,700 1000 8.9 6,000 17,949 15,890
5 None 1999-09-02 1,600,000 200 3.1 10,000 17,672 16,142
6 None 1999-09-29 371,000 500 2.4 4400 13,928 11,107
3 1 None 1989-10-16 20,000 1000 45 9,000 21,714 18,767
2 AZT, ddC 1995-10-31 19,400 1000 12 2,300 3,837 2,406
3 3TC,d4T,PI 1997-05-27 74,800 1000 19 14,000 22,191 17,693
4 3TC,d4T,PI 1997-08-18 248,600 800 45 90,000 35,033 28,423
5 3TC,d4T,PI 1997-10-02 2,171,200 500 13 144,000 23,420 18,202
6 None 1998-05-04 385,000 1000 47 180,000 11,495 9,355
4 1 None 1994-11-15 54,400 1000 20 10,800 11,898 9,781
2 AZT, ddI 1996-06-03 112,000 1000 14 16,000 22,477 15,866
3 None 1997-07-02 83,100 1000 41 34,000 35,954 25,253
4 3TC,d4T,ddI,PI 1999-12-14 331,000 750 44 108,000 23,429 17,511
5 None 2002-08-16 160,000 1000 9.6 15,300 11,489 10,098
6 None 2002-10-13 356,000 800 59 166,600 10,874 9,375
7 ABC,d4T,TDF,PI 2003-02-24 234,000 800 25 47,600 9,405 7,641
8 ABC,d4T,PI 2003-09-15 68,200 1000 40 27,000 11,909 10,288
5 1 None 1994-06-07 40,000 1000 9.0 3600 22,974 19,104
2 AZT, ddI 1995-08-08 46,400 1000 5.0 2,300 23,625 18,299
3 3TC,AZT,ddC 1996-03-26 245,000 800 16 31,000 10,548 7,770
4 3TC,d4T,PI 1998-05-07 117,000 800 16 15,000 24,166 16,965
5 ABC,d4T,NNRTI,PI 1998-11-13 87,200 1000 18 16,000 22,449 15,575
6 ABC,d4T,NNRTI,PI 1999-01-26 235,000 800 1.3 2,400 20,918 15,157
6 1 AZT 1995-08-17 542,000 500 46 126,000 20,979 15,422
2 3TC,AZT,PI 1996-06-19 224,700 800 16 29,000 8,290 5,906
3 3TC,d4T,PI 1996-12-05 375,600 500 43 81,000 12,146 8,783
4 3TC,d4T,PI 1997-10-21 1,054,800 200 19 40,000 38,541 29,582
5 ABC,NNRTI,PI 1998-12-02 21,600 1000 17 3,600 41,940 35,401
6 ABC,PI 2001-01-04 349,000 500 18 32,000 11,004 8,182
7 None 2001-02-15 200,000 600 1.9 2,300 24,727 20,082
8 None 2001-07-02 250,000 600 1.8 2,700 29,233 25,038
Footnotes
a3TC; lamivudine, ABC; abacavir, AZT; zidovudine, d4T; stavudine, ddI; didanosine, ddC; zalcitabin, TDF; tenofovir, EFV; efavirenz, NNRTI; non-nucleoside reverse
transcriptase inhibitor; PI; protease inhibitor.
bTime point for sampling.
cIn plasma.
dPlasma volume used for extraction.
eRNA recovery after extraction/cDNA synthesis efficiency.
fcDNA templates subjected to UDPS.
jUDPS reads before cleaning.
kUDPS reads after cleaning.
doi:10.1371/journal.pone.0011345.t001
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PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11345Figure 1. Frequency of resistance drug resistance mutations M184V, T215Y, L210W and T215C/D before, during and after
treatment. Treatment history is indicated by bars below each patient’s graph; AZT; zidovudine, 3TC; lamivudine, d4T; stavudine, ddI; didanosine,
ABC; abacavir, ddC; zalcitabine, TDF; tenofovir, NNRTI; non-nucleoside reverse transcriptase inhibitors, PI; protease inhibitors. Arrows indicate time for
sampling. The dashed horizontal lines indicate the detection limit in each patient. ND: not detectible.
doi:10.1371/journal.pone.0011345.g001
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Before UDPS the PCR amplicons were purified using the GE
PCR purification kit (GE health care, Pollards Wood, United
Kingdom) and the DNA concentration and purity was determined
using Nanodrop (Thermo Fisher Scientific, Waltham, US). In
addition, the Agilent 2100 bioanalyzer (Agilent Life Science, Santa
Clara, California, US) was used to verify the quality and length of
the amplicons. After quality controls, PCR amplicons from eight
samples were pooled in equimolar concentrations and sequenced
in both forward and reverse direction on the 454 Life Science
platform (GS-FLX, Roche Applied Science) according to the
manufacturer’s instructions.
Sanger sequencing
To facilitate the UDPS data cleaning processes and to verify the
sample authenticity the pol gene of all samples was also subjected
to direct population Sanger sequencing (ABI Prism 3100) using
Big Dye terminator cycle sequencing kit according to recommen-
dations by the manufacturer (Applied Biosystems, Foster City,
California, US). To identify possible contamination between
specimens the population sequences were used to reconstruct
neighbor-joining phylogenetic trees with the MEGA 4.0 software
using the maximum composite likelihood model with gamma
distributed rates across sites (a=0.5) [23]. Statistical support for
internal branches in the tree was obtained by 1000 bootstrap
replicates. The sequences showed a patient-specific clustering with
high bootstrap support (.90%), which argues against the
occurrence of contamination and sample mix-up (data not shown).
Control experiments
PCR and UDPS errors. To measure the accuracy of our
UDPS protocol, the SG3Denv plasmid was diluted to 1 copy,
amplified using the optimized protocols described above and
subjected to UDPS. The entire procedure from sample
preparation to UDPS was repeated three times. The sequence of
the plasmid clone was determined by Sanger sequencing and any
difference from the Sanger sequence in the UDPS analysis was
assumed to be a PCR or UDPS error. Based on these data we
estimated the average frequency sequencing errors in the analyzed
fragment as well as the frequency of sequencing errors at each
nucleotide position. We calculated statistically derived cut-off
values for detection of all possible mutations at each position.
In vitro recombination. The frequency of in vitro
recombination during the PCR was evaluated by mixing two
clones. The plasmid clones were generated from patient samples
using TOPO TA cloning kit (Invitrogen, Carlsbad, California,
US). Two plasmid clones, that contained 14 informative sites
disbursed over the amplicon, were mixed in equal proportions and
diluted to 10,000 templates and 100,000 templates before PCR
amplification and UDPS.
Data cleaning strategy
New bioinformatic software was written to manage, clean and
analyze the UDPS data (Jernberg et al., manuscript in prepara-
tion). The software was inspired by Tsibris et al. [24] who kindly
made their code available to us before publication. Since eight
samples were analyzed simultaneously by UDPS in each physical
field of the Picotiter plate, reads from each individual sample were
first identified using the sample-specific sequence tags in the
primers (see Table S2). Next, the data was cleaned by a set of
scripts that discarded; 1) all reads with ,80% similarity to the
corresponding Sanger sequence, 2) reads containing ambiguous
bases (Ns), 3) reads that did not cover the region of interest (amino
acids 180–220 in RT, position 3087 to 3206 in HxB2, GenBank
accession number K03455). Remaining reads were imported into
the GS amplicon software (Roche, Penzberg, Germany) and
aligned. The alignment was extracted and the amount of data was
compressed by scripts that identified unique sequence variants in
forward and reverse direction and counted the number of reads
per variant. The tally for each variant was retained with the
sequence name for further analyses. The alignment was cut to the
region of interest (amino acid 180–220) and gaps were removed.
Since UDPS errors are known to be concentrated to homopol-
ymeric regions, reads with out-of frame insertions or deletions
were removed. Finally, the alignments were manually inspected
and any remaining variants with frameshifts or stop codons were
removed.
After editing, the tallies for the forward and reverse sequence of
each variant were compared and the abundance of the variant was
set to the sum of the forward and reverse tallies. However, if
frequency of the forward and reverse reads differ by more than a
factor of 10 we made the assumption that a systematic error had
occurred during 454 sequencing and adjusted the frequency to the
lower of the two estimates. Finally, the variant was discarded from
further analyses if the variant was absent in either forward or
reverse direction.
Drug resistance analyses
Individual cut-off values were calculated for all drug resistance
mutation positions using the clone data obtained from three
different UPDS runs, which we refer to as 1, 2 and 3. The
nucleotide sequences were translated into amino acid sequences.
Three error rates (1, 2 and 3) for all positions were calculated using
all reads in every position. The error rates were calculated by
estimating the number of mismatches between all the UDPS reads
generated from the SG3Denv plasmid and the corresponding
Sanger sequence.
The error rates (1, 2 and 3) were combined to one average error
rate and a 95% confidence interval was calculated. This was
estimated for every drug resistance mutation (Jernberg et al.
manuscript in preparation). Based on these error rates and the
number of reads from the clone data and the number of reads in
each patient sample we calculated individual cut-off values (p-
value ,0.05) for all resistance mutations in all samples using a
Chi-square test with correction for continuity.
Variant analysis
Variants were classified as high-confidence variants or as
probable sequencing artifacts in the following way. The
Needleman-Wunsch algorithm was used to construct pairwise
alignment between the Sanger sequence of the SG3Denv
plasmid and UDPS clonal reads. The errors per nucleotide
from all pairwise comparisons were added together and divided
by the number of reads. Each of the three data sets was analyzed
separately and an overall average and cut-off values were
calculated in the same way as for the drug resistance analyses.
Variants with prevalence higher than the cut-off values were
classified as high-confidence variants and were retained for
further analyses and variants below the cut-off values were
discarded. The genetic distance of each variant from the most
prevalent variant in the first sample of the patient was calculated
by computing pair-wise distance in MEGA 4.0 using the
Tamura-Nei model with gamma distributed rates across sites
(a=0.5) [23]. The total nucleotide diversity between all high-
confidence variants in each patients sample was determined by
computing the average pair-wise distance weighted according to
t h ep r e v a l e n c eo fe a c hs u c hv a r i a n t .
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Sample preparation and UDPS data cleaning
In this study we have used the UDPS technology to dissect the
HIV-1 quasispecies evolution in longitudinally collected plasma
samples from six HIV-1 infected individuals. The pre-UDPS
protocols, i.e. the RNA extraction, cDNA synthesis and PCR,
were carefully optimized for high recovery. The number of
recovered cDNA molecules was quantified by limiting dilution
PCR and compared to the HIV-1 RNA levels of the original
plasma samples. These analyses showed that the number of cDNA
molecules subjected to UDPS ranged from 2,300 to 570,000 and
that the RNA extraction and cDNA synthesis methods had a
combined efficiency that ranged from 1.3% to 100% (Table 1).
The low efficiency of preparation for some samples could possibly
be explained by sample storage conditions since most samples had
been stored at 270uCo r220uC for long time and sometimes also
had been repeatedly freeze-thawed. From the UDPS we obtained
a total of 800,615 reads with a median of 20,949 (range 3,837 to
41,490) reads from each sample, which agreed well with the
25,000 reads per sample that we had aimed at. The UDPS data
were cleaned to remove reads with PCR and UDPS artifacts while
retaining as many high-confidence sequences as possible (see
Materials and Methods). During this process a median of 20%
(range 9%–37%) of the reads were discarded from each sample so
that a median of 16,016 (range 2,406–35,401) reads remained
from each sample. Information about treatment, plasma viral
levels, number of viral templates recovered and number of reads
before and after data cleaning are shown in Table 1.
Validation of UDPS
New technologies such as UDPS need to be validated.
Therefore, we performed several control experiments. The results
from these experiments were used to investigate UDPS sequencing
errors, determine in vitro recombination rates, calculate the
sequencing depth and compute cut-off values for detection of
resistance mutations and minority sequence variants.
Estimation of UDPS error rate and cut-off values for
detection of minority resistance mutations. To measure the
accuracy of the UDPS, we sequenced the SG3Denv plasmid clone
in three separate UDPS runs, which generated a total of 45,679
sequence reads (after data cleaning). From these data we estimated
that the average error rate of UDPS after data cleaning was less
than 0.05% errors per nucleotide compared to 0.54% before data
cleaning. Thus, our cleaning strategy decreased the error rate
approximately 10-fold. The error rate was not uniform across sites
(Jernberg et al, manuscript in preparation). For this reason we
calculated the UDPS error rates for each nucleotide position
associated with drug resistance and used the upper limit of the
95% confidence interval as cut-off value for detection of
mutations. The cut-off values for the resistance mutations
relevant for this study are summarized in Table 2. As illustrated
in Table 2, the possibility to detect minority resistance mutations
depends not only on the UDPS error rate, but also on the
sequence depth. Thus, cut-off values for detecting resistance
mutations were individually calculated for every sample using a
Chi-square test with correction for continuity.
Low frequency of in vitro recombination. The frequency
of in vitro recombination during the PCR was evaluated by UDPS
analysis of 100, 000 and 10,000 templates from a mixture of two
clones, which differed at 14 nucleotide positions. The overall
proportion of recombinant sequences prior to data cleaning was
0.76% and 0.27%, respectively. After data cleaning, no
recombinant variants were detected in the 10,000 template
mixture while two recombinant variants were detected in the
100,000 template mixture at proportions of 0.22% and 0.18% of
the total number of sequences, respectively. Thus, PCR
recombination was rare and is unlikely to have influenced our
results.
Prevalence of drug resistance mutations before, during
and after failing treatment
Significant preexistence of the M184I, T215A and T215I
mutations. Pre-treatment samples were available for five of the
six patients. The M184I resistance mutation was detected in the
virus populations from four of five patients (patients 1, 2, 3, and 5)
at levels that ranged from 0.07% to 0.09% (Table 3). The M184I
mutation confers high-level of resistance (about 1000-fold) to 3TC
[25] and during treatment failure it is known to appear transiently
before being replaced by M184V [26,27]. We also investigated the
levels of preexisting T215 reversion mutations (T215A/C/D/E/
G/H/I/L/N/S/V) and found that four of five patients had
preexisting levels of T215A and/or T215I that ranged from 0.05%
to 0.11% (Table 3), whereas we did not detect any of the other 215
reversion mutations. Our results show that T215A and T215I not
only evolve following treatment interruption in patients with
failing therapy, but also can exist as minority variants prior to any
therapy.
No detectable pre-existence of the M184V, T215Y/F and
NNRTI resistance mutations. None of the five individuals
had significant levels of Y181C/I/V, M184V, Y188C/L/H,
G190S/A, L210W, T215Y/F and K219E before treatment
(Table 3). Thus, we did not detect significant pre-treatment
levels of the three important NRTI resistance mutations (M184V,
T215Y and T215F) nor the three important NNRTI mutations
(Y181C/I/V, Y188C/L/H and G190S/A). However, it should be
noted that M184V was observed, but the levels of this mutation
were not above the statistically derived cut-off value, because the
error rate was comparably high for this mutation (median cut-off
value 0.17%) (Table 2).
Transient increase of M184I during treatment failure.
From patients 2 and 5, we had samples taken three and four
months after the start of 3TC containing therapy, respectively. At
this time, the M184I mutation had increased from 0.08% to
0.27% in patient 2 and from 0.08% to 63% in patient 5 (Fig. 1).
However, the M184I mutation was completely replaced by
M184V after 8 months of 3TC treatment in patient 2 and 3
years in patient 5. In the three remaining patients no detectable
levels of M184I was observed in the first available sample after
start of 3TC therapy, which was obtained between 9 month to 2
years (patients 1, 3 and 4) after start of therapy. Instead, in these
patients the M184V mutation dominated and was found in 99.5–
99.9% of the virus population (Table 4).
During treatment failure almost 100% of the virus
population displays resistance mutations. Drug resistance
mutations evolved during suboptimal treatment in all six patients.
All patients developed the M184V mutation, four patients
developed T215Y and three developed L210W. The M184V
mutation increased in prevalence during failing 3TC-containing
regimen in all patients and finally constituted between 99.5% and
99.9% of the viral quasispecies (Fig. 1 and Table 4). In two of the
four patients (patients 1 and 3) the T215Y mutation also increased
gradually from 78 and 90.3% after approximately 16 months of
AZT-containing treatment to 99.9% 12 months and 19 months
later, respectively. In the remaining two patients who developed
the T215Y mutation (patients 5 and 6), no gradual increase was
observed and a prevalence of 99.9% was seen after 5 to 13 months
of treatment (Fig. 1 and Table 4).
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patients 2 and 4 despite failing AZT/d4T containing regimen,
which could indicate that the adherence to AZT/d4T treatment
was too low to drive development of resistance [28]. Taken
together, drug resistance developed quickly in all patients and
increased gradually until almost the entire quasispecies was
resistant.
Almost complete disappearance of resistance mutations
from plasma virus during treatment interruption. Five of
the six patients were sampled during treatment interruption. In
patient 6 the level of resistance was still high 2 weeks after
treatment interruption when M184V and T215Y was found in
98.5% and 99.3% of the quasispecies, respectively (Table 5, Fig. 1).
However, after prolonged treatment interruption the prevalence of
the resistance mutations rapidly decreased and after five month
the M184V mutation was undetectable and the T215Y present at
0.10% (Table 5). In patient 1 and 4 low frequencies of M184V
were found 1 and 3 months after treatment interruption,
respectively, representing 2.3% and 3.9% (Table 5). In contrast,
patient 2 and 4 had undetectable levels of M184V already 3 and 6
months after 3TC interruption, respectively (Table 5). Thus, the
M184V resistance mutations decreased quickly after treatment
interruption in all five patients. However, the rate of decay of
M184V varied and after 3–8 months the mutation was not
detectable in virus from plasma.
Table 2. Estimated cut-off values for detection of selected
drug resistance mutations.
Mutation
Upper limit
(n=2406)
a
Median
(n=16016)
b
Lower limit
(n=35401)
c
Y181C 0.17% 0.07% 0.06%
Y181I 0.04% 0.02% 0.01%
Y181V 0.04% 0.02% 0.01%
M184V 0.29% 0.17% 0.16%
M184I 0.17% 0.07% 0.06%
Y188C 0.25% 0.15% 0.13%
Y188H 0.25% 0.14% 0.12%
Y188L 0.04% 0.02% 0.01%
G190A 0.04% 0.02% 0.01%
G190S 0.04% 0.02% 0.01%
L210W 0.04% 0.02% 0.01%
T215Y 0.04% 0.02% 0.01%
T215F 0.04% 0.02% 0.01%
T215I 0.17% 0.07% 0.06%
T215N 0.04% 0.02% 0.01%
T215S 0.04% 0.02% 0.01%
T215A 0.08% 0.02% 0.02%
K219Q 0.04% 0.02% 0.01%
K219E 0.04% 0.02% 0.01%
Footnotes
aThe upper limit cut-off value represent the 95% confidence interval for a
sample with 2406 reads, which was the lowest number of reads analyzed from
a patient sample in this study.
bThe median cut-off value represent the 95% confidence interval for a sample
with 16016 reads, which was the median number of reads analyzed in the
patients samples in this study.
cThe lower limit cut-off value represent the 95% confidence interval for a
sample with 35401 reads, which was the highest number of reads analyzed
from a patient sample in this study.
doi:10.1371/journal.pone.0011345.t002
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As described above our control experiments using mixtures of
HIV clones showed that in vitro recombination was rare with our
experimental protocol. This allowed us to track individual HIV
variants over time. Thus, we determined the number of variants in
each sample to investigate the population dynamics of HIV-1 in
our six patients. The number of variants ranged from 221 to 1729
in the six patients, but most variants were only represented by a
small number of reads and their frequency did not exceed the
statistically derived cut-off values for detection of high-confidence
variants (see Materials and Methods). The number of high-
confidence variants ranged from 17 to 76 (Table 6).
Decreasing number of genetic variants during
development and reversion of resistance. In all patients
the number of genetic variants decreased over time and there were
significantly fewer variants present in the last sample as compared
to the first sample from each patient (p=0.028, Wilcoxon
matched pairs test) (Table 6). This suggests that the viral
populations had undergone genetic bottlenecks during the
development and reversion of resistance. We also analyzed
changes in genetic diversity over time and did not find any
changes that clearly could be related to changes in treatment
(Table S3). However, it should be pointed out that the study was
not designed to analyze changes in diversity.
High degree of linkage between drug resistance
mutations during treatment failure. In Figure 2 and
Figure 3 the 10 most common variants in each time-point and
their genetic distance from the most common variant in the first
sample is plotted for each patient. Patient 1 started on AZT
monotherapy in the end of 1995 and had 3TC added eight months
later (Fig. 2, patient 1). Nine months after 3TC introduction
variants that only had the M184V mutation co-existed with
variants with linked M184V and T215Y mutations. However,
during prolonged 3TC containing treatment the M184V variants
were completely replaced by the M184V-T215Y variants,
suggesting that the M184V-T215Y variants were more fit during
selection pressure from 3TC, d4T and ddI. It is interesting to note
that several different M184V-T215Y variants co-existed,
suggesting that they did not all arise through recombination but
by convergent selection on these sites. Similar patterns were
observed in all patients in whom more than one drug resistance
mutation emerged (patients 2 and 3 in Fig. 2, patient 5 and 6 in
Fig. 3).
During maximum levels of resistance no wild-type variants were
detected in plasma from five of the six patients. However, in
patient 2 wild-type variants were detected in the first two samples
during treatment (Fig. 2). Since this patient did not develop the
T215Y/F mutations despite a failing AZT containing regimen, we
cannot exclude problems with adherence [28]. Thus, wild-type
variants were rarely detected in the replicating plasma virus
population during treatment failure, even with our highly sensitive
assay.
Treatment interruption resulted in reappearance of
archived wild-type variants or reversion of resistance
through continued evolution. In four of the six patients
(patients 1, 2, 3 and 4) we were able to analyze the origin of the
drug-sensitive variants that re-appeared during treatment
interruption. For patient 1, 2 and 4 the reappearing drug-
sensitive variants were identical to wild-type variants that were
present before therapy was initiated (Fig. 2 and Fig. 3). In patients
1 and 4, none of drug sensitive variants were detected during
treatment, suggesting that the rebounding drug-sensitive variants
originated from archived virus in latent reservoirs. For patient 2,
two different drug-sensitive variants were detected during
treatment. None of these existed before treatment, whereas one
Table 4. Highest levels of drug resistance detected during
treatment.
Patient Mutation %
M184V L210W T215Y
1 99.9 - 99.9
2 99.5 - -
3 99.8 99.9 99.9
4 99.9 0.117 -
5 99.8 99.8 99.9
6 99.6 99.9 99.9
doi:10.1371/journal.pone.0011345.t004
Table 5. Prevalence of drug resistance mutations during treatment interruption.
Patient Sample Stop of treatment Mutations %
c
3TC/ABC
a AZT/d4T
b M184V M184I L210W T215Y T215C T215D T215A T215G T215I
15 1 m o 1 m o 2.32 0.04 0 1.03 00000 . 0 5
6 8 mo 8 mo 0.01 0.06 0 0 0 0 0.01 0 0.08
2 5 3 mo - 0.07 0.06 0.02 000000
6 4 mo - 0.07 0.06 0 0 0 0 0.01 0 0.01
3 6 6 mo 3 mo 0.14 0.1 9.68 27.6 62.3 6.04 0.01 0.01 0
43 1 m o - 0.71 0.06 0.02 0.02 000.02 0 0.07
51 m o - 1.07 0.11 0.04 0000.03 0 0.07
63 m o - 3.88 0.1 0.12 0000.06 0 0.04
6 7 0.5 mo 2 yr 4 mo 98.5 0.01 99.2 99.3 0.02 0 0.01 0 0
8 5 mo 2 yr 9 mo 0.04 0.04 0.04 0.1 0 0 0.02 0 0.6
Footnotes
a3TC, lamivudine; ABC, abacavir.
bAZT, zidovudine; d4T, stavudine.
cNumbers in bold are above the statistical cut-off values.
doi:10.1371/journal.pone.0011345.t005
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interruption. In patient 3, a completely different pattern was
observed and none of the variants detected before treatment were
observed after treatment interruption. Instead, the drug-sensitive
variants that appeared after 3 and 6 months after 3TC and d4T
treatment interruption, respectively, had reversion mutations at
position 215 (Fig. 2). None of these ‘‘reversion’’ variants were
detected before or during therapy, suggesting that they evolved
from resistant variants rather than originated from archived virus
in latent reservoirs. Finally, none of the 10 most common variants
during treatment interruption had the M184V mutation, which
was present in multiple variants during treatment failure. This
suggests that this mutation had independently reverted to wild-
type in several different drug resistant variants. For patient 5 and 6
we were not able to draw any conclusions on the origin of non-
resistant virus during treatment interruption since samples before
treatment (patient 6) or after treatment (patient 5) were not
available.
Discussion
In this study, we have used the UDPS technology to study the
evolution of drug resistance and to detect minority virus variants in
HIV-1 pol from six longitudinally followed patients. We optimized
all pre-UDPS protocols and developed new data cleaning
strategies. This allowed us to identify minority resistance mutations
and viral variants that constituted as little as 0.05% of the viral
quasispecies, enabling detailed studies of the viral dynamics during
ART. We found no or very low levels of drug resistance before
treatment, but during treatment failure resistant viruses effectively
out-competed wild-type variants and constituted almost 100% of
the viral population. When treatment was interrupted drug
resistant viruses disappeared rapidly and were undetectable in
plasma as early as after 3 months.
The sensitivity of UPDS depends on the number of viral
templates that can be successfully extracted and amplified from a
plasma sample [12,29], the error rate of PCR and UDPS and
efficiency of cleaning the UDPS data from such errors. In previous
UDPS studies of HIV resistance, the sensitivity usually has been
limited by template numbers because relatively small sample
volumes were used and the actual number of templates subjected
to UDPS was low or not quantified [18,19,30,31]. Furthermore,
the sequence depth has been relatively low, i.e. approximately
500–3600 reads per base in these studies of HIV-1 resistance
[12,18,19,30,31]. Therefore, the lower limit of detection of minor
resistance mutations was estimated to be 0.5–3.0% in the previous
studies [12,18,19,30,31]. Here, we have used optimized pre-UDPS
protocols (i.e. RNA extraction, cDNA and PCR) and quantified
the number of HIV cDNA templates subjected to UDPS, which
ranged from 2,300 to 570,000. Furthermore, we have sequenced
considerably deeper (median 20,949 reads, range 3,837–41,940)
than earlier investigators. For these reasons the sensitivity of our
UDPS was primarily limited by errors introduced during PCR and
UDPS. Thus, it was a challenge to distinguish rare, but genuine,
variants from sequencing artifacts. By analyzing the frequency and
distribution of sequencing errors in experiments on plasmid clones
we were able to develop bioinformatic software to clean data from
sequencing artifacts and to determine statistical cut-off values for
detection of high-confidence minority resistance mutations and
genetic variants. The error rate across sites was 0.05% (95%
confidence, upper limit) after data cleaning, which is lower than
the previously reported 0.1% to 1%[16,17,18,19,24,32]. Conse-
quently, our cut-off values for detection of high-confidence
resistance mutations and viral variants are considerably lower
than in previous studies. As expected, the error rate was not
uniform across sites. For this reason we estimated the UDPS error
rate for each drug resistance position (Jernberg et al, manuscript in
preparation). These cut-off values were also dependent on the
number of reads, but resistance mutations that represented on
average 0.05% (range 0.014–0.29%) and viral variants that
represented on average 0.11% (range 0.09–0.21%) were high-
confidence, i.e. exceeded our statistically derived cut-off values.
Thus, by using optimized pre-UDPS protocols and effective data
cleaning strategies, we have been able to increase the sensitivity for
detection of genuine virus variants so that variants within the HIV-
1 quasispecies that are as rare as 1 in 1000 can be reliably
detected. This has to our knowledge not been achieved before for
HIV resistance studies. However, comparable detection limit was
reported in one study of the HIV-1 envelope gene [24]. For some
samples the number of sequence reads exceeded the number of
viral templates, which means that some templates were resampled.
Such resampling affects the sequencing depth, since it is not
possible to sequence deeper than the number of input templates.
However, we quantified the number of templates and the lowest
number of templates was 2,300, resulting in a theoretical depth of
0.04% (1/2300), but for most samples the template input number
was higher.
Mutations associated with drug resistance are expected to occur
naturally within the HIV quasispecies, even if a patient has never
received ART [5]. By simple calculations, using a reverse
transcriptase error rate of 3.4610
25 mutations per site and
generation [3,4] and viral production rate of 10
10 [7] it can be
estimated that all nucleotides in the HIV-1 genome on average
Table 6. Number of significantly detected viral variants throughout the study period for each patient.
Patient Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8
1 57
a 17
b 38 33 17
c 30 - -
2 72 23 44 32 22 21 - -
3 59 76 30 30 25 49 - -
4 73 76 70 43 35 43 21 32
5 65 53 40 44 24 46 --
6 63 42 38 31 35 44 54 31
Footnotes
aVariants in italic are sampled before any treatment is initiated.
bVariants in bold are sampled during treatment failure.
cVariants in normal text are sampled during treatment interruption.
doi:10.1371/journal.pone.0011345.t006
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5 times per day in an HIV-1 infected individual.
However, it is not known at what frequency these mutations are
present and if they in some situations may be of clinical relevance.
In this study we found significant levels of M184I (4 of 5 patients),
T215I and/or T215A (4 of 5 patients) ranging from 0.02%–0.12%
in plasma samples obtained before treatment was initiated. In
contrast, we did not find any significant pre-existence of the major
drug resistance mutations M184V, Y181C, Y188C or T215Y/F.
The presence of M184I, T215I and T215A in treatment naı ¨ve
patients is somewhat expected since these drug resistance
mutations only differ by one nucleotide from wild-type. For the
same reason we would have expected to find M184V, Y181C and
Y188C, but not T215Y/F since the latter are double mutants
compared to wild-type. One explanation for the absence of
significant levels of M184V, Y181C and Y188C could be that the
cut-off values were higher at these positions (e.g. 0.15% for
M184V compared to 0.07% for M184I) or that these mutations
are associated with a higher fitness cost. However, Johnson et al
[33] developed sensitive real-time PCRs and estimated the
absolute assay sensitivities on a clone as well as the natural
occurrence of several resistance mutations, including M184V,
Y181C, T215Y and T215F, in 138 treatment naı ¨ve patients with
samples collected before the ART era. They found evidence of
natural occurrence of all four resistance mutations at low levels
and the cut-off values for detection of high-confidence minority
resistance mutations (transmitted or acquired) were determined to
be 0.5%, 1.0%, 1.0% and 0.7%, respectively. Since the detection
limits of our UDPS technology are below these cut off values,
(0.15%, 0.07%, 0.02% and 0.02%, respectively) it is surprising that
we did not find any of these mutations in our pre-treatment
samples.
It is interesting to note that we found significant levels of M184I,
but not M184V, before treatment in 4 of 5 patients. This agrees
with early data from 3TC mono-therapy studies where it was
shown that M184I usually occurs transiently before being replaced
by M184V, which is more fit in the presence of 3TC [26,34].
Several possible explanations have been proposed for the transient
occurrence of M184I. Our data indicate that the primary reason
may be a higher pre-treatment level, which in turn may be due to
one or several of the proposed underlying mechanisms. It has been
proposed that this initial appearance of M184I is due to the
balance between mutational bias of RT and selective pressure. For
HIV, G-to-A mutations are more common than other mutations.
Thus, there is a higher production rate of M184I than M184V
since the wild-type methionine is coded ATG and the resistance
mutations to isoleucine and valine are coded ATA and GTG,
respectively [34,35]. In addition, in vitro studies have shown that
the mutation rate from wild-type to M184I is more than four times
higher than that to M184V, while the enzymatic efficiency of a RT
with M184I is approximately 50% lower than that of a RT with
M184V [36]. Therefore, the bias for G-to-A mutations of HIV-1
works in favor for M184I, while the selective pressure for
enzymatic efficiency selects for M184V.
Our analyses of HIV-1 variants showed that different wild-type
variants co-existed before initiation of therapy. Following start of
therapy, virus variants with several different combinations of
resistance mutations evolved and co-existed (Fig. 2 and Fig. 3).
However, during prolonged treatment failure the number of viral
variants decreased, suggesting genetic bottle-necking. This was
accompanied by a gradual increase in the prevalence of variants
with specific linked drug resistance mutations (in particular
variants with M184V+T215Y and M184V+L210W+T215Y)
(Table 4; Fig. 2 and Fig. 3) and wild-type variants were only
detected in one patient during therapy. This finding indicates that
wild-type variants had very low fitness during therapy and that
very little wild-type virus was produced from viral reservoirs in
latently infected cells, such as memory CD4+ T-lymphocytes.
However, it is likely that wild-type variants still were present in
plasma at levels below our detection limit of 0.05% because it is
well known that there is residual viremia during long-term
successful ART, that these viral variants often are drug-sensitive
[37,38,39] and that this residual viremia is due to virus release
from stable reservoirs of infection [40]. In contrast to our results,
Allers et al. reported significant levels (0.6 to 30%) of lamivudine-
sensitive variants in viral population from patients with failing
3TC-containing therapy [41]. However, these patients received
dual-therapy with 3TC and AZT, while our patients generally
received three or more drugs.
Since many drug resistance mutations reduce replication fitness
[42], drug-sensitive viruses rapidly evolve after complete treatment
interruption [13,43]. However, the kinetics and detailed dynamics
of this process are largely unknown. In this study we have shown
that drug resistant variants decreased to undetectable levels a few
months after complete treatment interruption. This indicates that
these resistant variants have very low fitness in the absence of
therapy. The complete out-growth of drug-sensitive variants
within a few months differs markedly from the findings in patients
with transmitted drug resistance, where drug resistance may persist
for many years [44,45,46]. Our findings might be of clinical
relevance since we show that drug resistant variants may be very
difficult to detect in patients with previous treatment failure even
with highly sensitive UDPS technology. At some variance with our
data, Le et al. found low abundance mutations associated with
AZT/d4T resistance 2 to 7 years after treatment with these drugs
had been stopped. However, in contrast to our patients, the
patients enrolled in their study continued therapy with other
antiviral drugs. Thus, additional studies are needed to investigate
the dynamics of drug resistant variants after treatment interrup-
tion. Since drug resistant variants can become established in long-
term reservoirs [44,47], it would be interesting to analyze different
cell compartments in addition to plasma.
In conclusion, we have developed optimized UDPS protocols
that have decreased the UDPS error rate and thereby increased
the sensitivity for detection of minority HIV-1 resistance mutations
and viral variants. With this technology we were able to identify
and quantify variants that represented as little as 0.05% of the
HIV-1 quasispecies. We have shown that the levels of preexisting
drug resistance in plasma samples from treatment naı ¨ve patients is
very low and that several important drug resistance mutations
(M184V, Y181C, Y188C and T215Y/F) were not detectable in
Figure 2. HIV-1 variant dynamics before, during and after treatment. For each patient the 10 most common variants in each time point are
illustrated as circles (if recurring) or as cubes (if not recurring). The genetic distance of the variants in nucleotide changes/site (from the most frequent
variant at the first time-point) is plotted over time. The frequency of the variants is proportional to the area of the circles and cubes. Treatment history
is indicated by bars below each patient’s graph; AZT; zidovudine, 3TC; lamivudine, d4T; stavudine, ddI; didanosine, ABC; abacavir, ddC; zalcitabine,
TDF; tenofovir, NNRTI; non-nucleoside reverse transcriptase inhibitors, PI; protease inhibitors. Arrows indicate time for sampling. The genotype of the
variants is color-coded, thus each combination of drug resistance mutations have a specific color (see guide to the right unique for each patient).
There are at maximum six shades of each color enable means to follow specific variants over time. Thus, the most common variant receives the first
shade and so on. The last shade is used for the remaining variants and for the non-recurring variants.
doi:10.1371/journal.pone.0011345.g002
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these mutations are below our detection limit. Furthermore, there
was almost 100% replacement of wild-type and drug-resistant
variants during treatment failure and treatment interruption,
respectively. Thus, our study shows that UDPS can be used to gain
new insights in HIV evolution and resistance and is relevant for
the possible future clinical use of this technology.
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